Additionally, the immune class had a higher level of tumor mutation burden (TMB), neoantigens (NeoAgs), tumor-infiltrating lymphocytes (TILs), and PD-1/PD-L1 expression than the non-immune class (Figure 5B–5F). This evidence concerns the gene CD274 and neoplasm.